Organoids of the female reproductive tract. by Chumduri, Cindrilla & Turco, Margherita
REVIEW
Organoids of the female reproductive tract
Cindrilla Chumduri1,2 & Margherita Y. Turco3,4
Received: 6 April 2020 /Revised: 9 December 2020 /Accepted: 14 December 2020
# The Author(s) 2021
Abstract
Healthy functioning of the female reproductive tract (FRT) depends on balanced and dynamic regulation by hormones during the
menstrual cycle, pregnancy and childbirth. The mucosal epithelial lining of different regions of the FRT—ovaries, fallopian
tubes, uterus, cervix and vagina—facilitates the selective transport of gametes and successful transfer of the zygote to the uterus
where it implants and pregnancy takes place. It also prevents pathogen entry. Recent developments in three-dimensional (3D)
organoid systems from the FRT now provide crucial experimental models that recapitulate the cellular heterogeneity and
physiological, anatomical and functional properties of the organ in vitro. In this review, we summarise the state of the art on
organoids generated from different regions of the FRT.We discuss the potential applications of these powerful in vitro models to
study normal physiology, fertility, infections, diseases, drug discovery and personalised medicine.
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Introduction
The successful birth of healthy offspring, necessary for the
continuation of the species, depends on the female reproduc-
tive tract (FRT). The FRT is responsible for regulating oocyte
maturation, providing the protective environment for
fertilisation and implantation of the embryo, as well as ensur-
ing access to nutrition for fetal growth. This process concludes
with parturition, and the FRT then undergoes remodelling to
allow repetition of this remarkable process. Across
allmammalian species there is a diverse range of reproductive
strategies, for example, in the length and regulation of the
estrous cycle, type of placentation and litter size, but the basic
features are generally shared (Fig. 1) [1]. The FRT is com-
posed of the ovaries, the site of maturation and release of
oocytes; the fallopian tubes (FT, also called oviducts) that
transport the oocytes to the uterus following ovulation; the
uterus where implantation of the embryo occurs and pregnan-
cy takes place; and the cervix which connects the uterus to the
vagina and is the entry site for male gametes as well as the
birth canal (Fig. 1). The cervix also acts as a barrier protecting
the upper FRT from invading pathogens.
The regulation of FRT function is complex and is coordi-
nated by hormones of the hypothalamus-pituitary-ovarian
(HPO) axis [2]. The differential hormonal responses between
the epithelial, stromal and immune populations provide anoth-
er layer of regulation locally within the tissues. Disruption of
these processes leads to a breakdown in homeostasis that may
result not only reproductive failure but also in a range of
disorders including endometriosis and carcinomas. These con-
ditions affect large numbers of women. There is still limited
understanding of their etiology and a lack of effective treat-
ment options [3, 4]. Furthermore, increasingmaternal age, diet
and environmental factors (e.g. presence of endocrine-
disrupting substances) and other changes in our lifestyle are
contributing to a rise in the incidence of these disorders [5–7].
Thus, a better understanding of the cellular and molecular
mechanisms controlling the function of the FRT is of increas-
ing importance.
Although there have been recent, major advancements in
reproductive research, key questions remain unresolved due to
the complexity of the FRT and the lack of tractable experi-
mental systems [8]. This is particularly true with regard to
understanding the normal physiology and molecular
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regulation of the human FRT. Although different types of
three-dimensional (3D) culture systems have been reported
for the FRT, the long-term, stable expansion of these primary
cells remains a challenge. The development of the 3D
organoid culture system by Sato and Clevers that allows the
culture and expansion of both normal and diseased cells in a
defined medium has been a transformative tool for the study
of many human tissues [9]. Organoids can be derived either
from pluripotent stem cells (PSC) or from tissue-derived stem
cells (fetal or adult). They are defined as cellular structures
that self-organise, consist of multiple cell types and emulate
key architectural, genetic and functional aspects of a specific
tissue [10].
There are several differences between PSC-derived and
tissue-derived organoids. PSC-derived organoids are generat-
ed by taking advantage of their inherent ability to undergo
differentiation and spatial patterning to adopt specific cell
fates in response to developmental cues [10]. Under specific
culture conditions which include signals from the wingless-
related integration site (Wnt), bone morphogenetic protein
(BMP), epidermal growth factor (EGF) and fibroblast growth
factor (FGF) pathways, PSC can be induced to undergo ‘or-
ganogenesis’ in a dish resulting in complex 3D structures that
resemble organs containing multiple cell types. Many types of
organoids have been derived from PSC, including intestine,
liver, stomach, kidney, lung and brain [11–16].
Tissue-derived organoids are generated by embedding
stem/progenitor cells into an extracellular matrix (ECM) (gen-
erally the commercially available Matrigel), which provides a
basement membrane-like structure, and grown under condi-
tions that mimic signals in the stem cell niche [9]. In contrast
to PSC-derived organoids, those derived from tissues are only
composed of epithelial cells. Tissue-derived organoids have
been established from almost all major organs in humans and
mice (reviewed in [10, 17]). Tissue-derived organoids can be
propagated and expanded long-term under their optimal cul-
ture conditions (≥ 6 months) [18]. Although different types of
organoids require a range of culture conditions,Wnt, EGF and
BMP pathways are key. There are species-specific differ-
ences; some human organoids like those derived from the
gut, pancreas and liver require additional factors to the corre-
sponding mouse organoid media, including inhibition of
transforming growth factor-beta (TGF-β) and p38 mitogen-
activated protein kinase (MAPK) pathways, nicotinamide and
forskolin [19, 20].
Recently, organoids have been generated from themurine and
human FRT. In this review, we discuss these recent advance-
ments with a focus on adult tissue-derived organoids and how
they are shaping the way we can study both the normal physiol-
ogy and disease of the FRT.We also highlight how this technol-
ogy has the potential to improve women’s health.
Anatomy and function of the adult human
female reproductive tract
The key aspect of adult stem cell-derived 3D organoids is that
they mimic the structure and function of the native adult tis-
sue. Here, we introduce the basic anatomy, function and his-
tology of the different parts of the FRT, with a focus on the
mucosal layer and its epithelial cells.
The ovaries
The ovaries are found in close proximity to the fimbria of the
FT and are kept in place by the ovarian ligaments attached to
the uterus (Fig. 1). The ovaries have two functions: to produce
and release mature oocytes into the FT and to act as an endo-
crine organ by secreting sex hormones oestrogen (E2) and
progesterone (P4) (Fig. 2) [21]. E2 and P4 direct the cyclical
Fig. 1 Anatomy of the human and mouse FRT. In humans, the FRT
consists of ovaries, fallopian tubes, uterus (endometrium and
myometrium), cervix (endocervix and ectocervix) and vagina. There are
some anatomical differences between the two species, as mice have a
bicornuate uterus (uterine horns) and oviducts are much less
pronounced in proportion to the rest of the reproductive tract
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changes of the mucosal lining of the uterus (endometrium)
and thus play a vital role in fertility and health of the FRT.
The ovaries are also the initial source of P4 once implantation
occurs, which is essential to sustain pregnancy in the first few
weeks [22, 23].
The ovaries are oval-shaped structures that can be divided
histologically into the outer cortex and inner medulla. In most
species, the cortex contains the follicles that are made up of
oocytes and the supporting follicular cells. Blood vessels and
lymphatics enter the ovary in the medulla. The HPO
hormonal axis regulates ovarian function [24]. At the begin-
ning of each menstrual cycle, several follicles begin to mature
under the influence of follicle-stimulating hormone (FSH) re-
leased by the pituitary (Fig. 2). The follicles themselves begin
to produce E2 and inhibin, inhibiting FSH production in a
negative feedback loop. The follicles continue to mature and
a peak in E2 production stimulates secretion of the luteinizing
hormone (LH) from the pituitary gland. This results in ovula-
tion where the follicle ruptures to release the oocyte from the
ovarian surface epithelium (OSE). The OSE consists of a sin-
gle layer of cuboidal epithelium, characterised by expression
of epithelial markers, including cytokeratins KRT7, KRT8,
KRT18 and KRT19, as well as mesenchymal markers
CDH2 and vimentin (Fig. 3) [25]. Notably, unlike other sim-
ple epithelia, CDH1 is rarely observed in ovarian epithelium
[26]. These molecular characteristics mean that OSE is plastic
with the capacity to undergo bidirectional epithelial-
mesenchymal conversion to allow repair of the ovarian sur-
face after ovulation [27]. The lifelong OSE homeostasis and
post-ovulatory repair in vivo are maintained by Leu-rich re-
peat-containing G protein-coupled receptor 5 (Lgr5)-express-
ing stem cells at the ovarian surface [28, 29]. Niche factors,
including EGF and TGFβ signalling, regulate epithelial–
mesenchymal transition (EMT) in OSE [29–31].
Upon ovulation, the oocyte is captured by the fimbria and
transported into the FT where fertilisation takes place. The
ruptured follicle transforms into the corpus luteum (CL) which
secretes E2 and P4. If fertilisation and implantation occur, the
CL continues to produce P4. In the absence of fertilisation, the
CL degenerates, forming the corpus albicans, concomitantly
resulting in a fall in P4 levels (Fig. 2). This triggers menstru-
ation and the restart of the cycle. Dysregulation of these
Fig. 2 The menstrual cycle. The
pituitary and ovarian hormones
regulating the menstrual cycle
and the morphological changes
occurring at the ovarian surface
epithelium (OSE) and endometri-
um are depicted. The menstrual
phase is divided into menstrual,
proliferative and secretory phases.
During the proliferative phase,
follicle-stimulating hormone
(FSH) promotes the growth of
ovarian follicles. This results in
rising levels of oestrogen (E2)
produced by the follicles which
then drives the proliferation of the
functional layer of the endometri-
um. Mid-cycle, a peak in E2 re-
sults in a surge of luteinizing
hormone (LH) and the release of
the oocyte (ovulation). This
marks the start of the secretory
phase, dominated by progester-
one (P4), which drives the differ-
entiation (decidualisation) of the
endometrium to prepare for im-
plantation. In the absence of im-
plantation, P4 levels drop trigger-
ing menstruation, the shedding of
the functional layer, to restart the
cycle. The basal layer is not shed
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processes is responsible for many disorders which include
ovarian cysts, ovarian carcinomas, disorders of the menstrual
cycle and polycystic ovarian syndrome [32].
The fallopian tubes
The FT are the link between the ovaries and the upper part of
the uterus providing the passage for the oocytes released from
the ovaries (Fig. 1). In humans, there are four sections of the
FT: the infundibulum, a funnel-like structure in contact with
the ovaries, the ampulla, the ampulla-isthmus junction and the
isthmus. The surface epithelium of the FT contains secretory,
ciliated and peg cells, and the segments differ in the proportion
of these cell types and the complexity of the longitudinal folds
present (Fig. 3) [33, 34]. The ciliated cells are particularly
abundant in the infundibulum and ampulla [33]. They are
essential for capture of the oocyte from the ovaries to guide
it into the ampullary-isthmus junction where fertilisation takes
place [35, 36]. Ciliated cells (acetylated α-tubulin+) are co-
lumnar and characterised by an oval nucleus with slender cilia
protruding into the lumen. The secretory cells (PAX8+) are
also columnar and contain apical secretory granules. Peg cells
are found intercalated between ciliated and secretory cells;
they have little cytoplasm and a dark staining nucleus [37].
All three cell types express epithelial cell adhesion molecule
(EpCAM) whilst the peg cells also express CD44 and integrin
α6 (ITGA6) (Fig. 3) [37, 38]. FT Pax8+ secretory cells act as
stem cells and are enriched in the distal portion of the mouse
FT including the fimbria [39–41]. Peg cells have secreted their
products into the lumen and are an exhausted subpopulation of
epithelial cells [42–45].
The uterus
The uterus is composed of myometrium, a thick layer of smooth
muscle, with an inner mucosal layer, the endometrium (Fig. 1). It
provides the protective environment for the embryo to implant
and to develop. The outermost layer in contactwith the peritoneal
cavity is the perimetrium. The myometrium undergoes contrac-
tions both in the non-pregnant state, during which it is thought to
play a role in guiding the embryo before implantation, and in
pregnancy to expel the baby at birth [46]. The endometrium is
further divided into an upper functional layer facing the cavity of
the uterus and the basal layer, juxtaposed to the myometrium
(Figs. 2 and 3). The functional layer contains the surface luminal
epithelium, upper portion of the glands whilst the basal layer
contains the basal, lower portion of the glands.
The endometrium has an essential role in implantation and
particularly during the early stages of pregnancy [47]. It is a
regenerative, dynamic tissue as it undergoes dramatic changes
in response to the ovarian hormones throughout the menstrual
cycle (Fig. 2) [48]. The morphology, ultrastructure and biochem-
ical characteristics of endometrial cells vary greatly throughout
the cycle. Extending up from the myometrial margin, long tubu-
lar glands open at the surface of the endometrium that is covered
by a luminal epithelium [49]. The luminal epithelium, like the
FT, contains both acetylated α-tubulin+ ciliated cells and
PAX8+ secretory cells (Fig. 3) [50]. The glandular epithelium
is composed mostly of columnar secretory cells with a few cili-
ated cells at the gland openings [51]. Both the non-ciliated lumi-
nal and glandular epithelium are positive for EpCAM, CDH1
and KRT7 (Fig. 3) [50]. The stroma beneath the endometrial
surface and between the endometrial glands contains CD10+,
vimentin+ mesenchymal cells that undergo dramatic changes
Fig. 3 The epithelia of the human FRT. The types of epithelia covering the different regions of the human FRT are illustrated. For each tissue the major
cell types are shown, with examples of typical markers they express. Markers with an asterisk are hormonally regulated
534 J Mol Med (2021) 99:531–553
during pregnancy [52]. The blood is supplied from spiral arteries,
and these play an important role in menstrual breakdown and in
supplying nutrients to the fetus during pregnancy [53].
In humans, rising levels of E2 after menstruation mark the
start of the proliferative phase during which the functional layer
is regenerated and grows considerably (Fig. 2). It is thought to
regenerate from the basal portion of the glands, which is not shed
[49, 54–56]. The basal glands express markers found in other
tissue stem cells/progenitors, including SRY-box transcription
factor 9 (SOX9), stage-specific embryonic antigen 1 (SSEA1)
and CDH2 (Fig. 3) [57–59]. This might be a stem cell compart-
ment, supported by the observation that CDH2+ cells can form
gland-like structures in vitro [57]. Recent studies have proposed
the existence of different bipotent stem cells in the murine endo-
metrium that are able to give rise to both luminal and glandular
epithelium and are spatially restricted to either the intersectional
zone (Foxa2+ cells) or basal region (Axin2+ cells) [60, 61]. The
luminal epithelium may also be a source of stem cells/progeni-
tors. LGR5, the receptor for Rspondin that potentiates Wnt sig-
nalling in stem cells of many tissues, is highly expressed in the
luminal epithelium especially during the proliferative phase in
humans (Fig. 3) [62]. In the adultmouse,Lgr5 is also hormonally
regulated but is restricted to the luminal epithelium during the
diestrus phase [63]. However, long-term lineage tracing shows
that they are not able to contribute to the different lineages, thus
suggesting that Lgr5+ cells are rather short-lived differentiated
cells of the adult endometrium in mice [63]. The murine endo-
metrium does not undergo shedding and regeneration so it is
likely that there are species-specific differences in how this tissue
is regulated.
After ovulation, during the secretory phase, the increase in P4
levels triggers the process of decidualisation, which results in the
specialised differentiation of the glands and stromal cells to pre-
pare for pregnancy, accompanied by characteristic morphologi-
cal and ultrastructural changes. The glands accumulate glycogen
in the subnuclear cytoplasm, and they begin to secrete copious
amounts of uterine milk proteins including glycodelin and osteo-
pontin [64]. The stromal cells increase in volume and produce
ECM proteins and play an essential role in the regulation of
epithelial behaviour through their secretions that signal to the
glands, including prolactin and insulin-like growth factor-
binding proteins (IGFBP) [65–67]. In the absence of implanta-
tion, falling levels of P4 that result from the involuting CL trigger
menstruation (Fig. 2). Decidualisation is essential for the estab-
lishment of pregnancy and defects in this process might contrib-
ute to several disorders of pregnancy (e.g. pre-eclampsia and
miscarriage) [68–70].
The cervix
The cervix links the uterine cavity with the vagina acting as a
physical barrier between the external environment (vaginal
canal) and the uterus (Fig. 1). The two major functions of
the cervix are to facilitate the passage of spermatozoa into
the uterine cavity and subsequently to FT where fertilisation
takes place and to maintain sterility of the upper FRT [71, 72].
It consists of two regions, the ectocervix and the endocervical
canal (endocervix). The endocervix is contiguous with the
uterine cavity from which it is separated by the internal os.
The ectocervix projects into the vagina. The external os marks
the transition from the ectocervix to the endocervical canal.
The columnar epithelium lining the endocervix meets the
squamous ep i t he l i um of the ec toce rv ix a t t he
squamocolumnar junction (SCJ) [73]. The SCJ undergoes dy-
namic modification and under certain physiological or patho-
logical conditions (influences of hormones especially in preg-
nancy, altered microbiota), the glandular epithelium at the SCJ
is replaced by squamous metaplasia, creating a transition or
transformation zone (TZ) [72, 74, 76].
The endocervical surface and gland-like crypts in the tissue
are covered by columnar epithelium with basal nuclei. These
epithelial cells express characteristic cytokeratins including
KRT8, KRT7 and KRT18 and renew very slowly (Fig. 3)
[77, 78]. Like the upper FRT, the columnar epithelium is
composed of two major cell types, ciliated and secretory cells
[76]. The secretory cells produce cervical mucus and the cil-
iated cells facilitate the movement of the mucus towards the
vagina to prevent ascending infections and support the en-
trance of spermatozoa into the uterus [74]. The squamous
epithelium of the ectocervix is composed of multiple layers:
basal, parabasal, intermediate and superficial layers sitting on
a basement membrane (Fig. 3). Cells move from the basal to
superficial layers accompanied by cell differentiation and flat-
tening (squamification) [79]. The cuboidal basal cells are pro-
genitor cells that are essential for constant tissue regeneration
and express the proliferation marker Ki67. The transit ampli-
fying cells in the parabasal layer have limited proliferative
capacity. Maturing squamous cells are present in the interme-
diate layer while the superficial layer consists of terminally
differentiated non-keratinised flattened cells that are ready to
exfoliate [79, 80]. The intermediate and superficial layers of
the cervix and vagina epithelium are rich in glycogen which
acts as a nutrient and supports the proliferation of healthy
microbiota like Lactobacillus [81]. The squamous stratified
epithelium is characterised by expression of cytokeratins in-
cluding KRT5, KRT14 and KRT17, distinct from those of
endocervix epithelium (Fig. 3) [78, 82]. Further, the transcrip-
tion factor Tp63, a homologue of the tumour suppressor gene
Tp53, is the master regulator and is essential for the develop-
ment of squamous epithelium [75, 83].
Two distinct types of sub-epithelial stromal cell compart-
ments underlie the ectocervical squamous and endocervical
columnar epithelium [78, 84]. The ectocervical stroma is des-
min+/smooth muscle actin (SMA)− whilst the endocervical
stroma is desmin−/SMA+/CD34+ [84]. The regenerative po-
tential of squamous and columnar epithelia is controlled by
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distinct Wnt signals from the stromal compartment.
Endocervical stromal cells express Wnt signalling agonists,
AXIN2 and RSPO1, whilst the ectocervical stroma expresses
a Wnt antagonist, Dickkopf-related protein 2 (DKK2), thus
creating an opposing Wnt microenvironment at the SCJ
[78]. The TZ is highly susceptible to persistent infections
and is the most common site for the development of cervical
neoplasia [85, 86]. Often squamous metaplasia precedes the
development of the majority of cervical cancers [87, 88]. In a
mouse model, a Wnt inhibitory environment promotes the
emergence of foci of reserve cells that undergo squamous
metaplasia; these are KRT5+ and are located under the colum-
nar epithelium [78].
The vagina
The vagina extends from the vulva to the uterine cervix (Fig.
1). It is distensible to allow for childbirth and is covered with
rugal mucosal folds. The vagina prevents potentially invasive
microorganisms from entering the uterus [89]. Healthy micro-
biota, including Lactobacillus acidophilus that colonise the
vagina, secrete lactic acid, maintaining an acidic environment
(pH 4.9–3.5) that reduces the chance of growth of pathogenic
microorganisms [90–93]. However, dysbiosis, where disrup-
tions in the healthy microbiome can allow even pathogenic
members of the microbiome to take hold, results in a variety of
infections with vaginitis being the most common [89, 94].
Despite the strong association with infection (e.g. human pap-
illomavirus (HPV) infection), neoplasms are relatively unusu-
al in this site, when compared with the development of carci-
noma of the cervix [95].
Similar to the ectocervix, the mucosa of the vagina is lined
with stratified squamous epithelium that is glycogenated and
nonkeratinising. Vaginal regeneration is dependent on the
basal cells that possess proliferative capacity and give rise to
the TP63+, KRT17+, KRT5+ and KRT14+ basal progenitor
cells and parabasal cells (Fig. 3). The differentiated interme-
diate layers express KRT13, CALML3 (calmodulin-like pro-
tein 3), KRT4 and IFITM3 (interferon-inducible
transmembrane protein 3) and apical cornified terminally dif-
ferentiated epithelium express KRT1 and KRT10 [96–98].
Organoids as a tool to study the female
reproductive tract
Many in vitro and in vivo models are being used to study the
biology and diseases of the FRT. Common in vitro models are
primary cells isolated from tissues, cell lines established from
carcinomas, tissue explants and 3D organotypic models
[99–103]. Although these are important tools, there are several
caveats. Primary cells have a limited life-span in culture and
the cell lines commonly used, ECC-1 (endometrial
carcinoma) and HeLA (cervical carcinoma), are karyotypical-
ly abnormal and do not represent the heterogeneity of the
initial tumour mass due to selection for cells with proliferative
capacity in vitro. Furthermore, many of the functions of the
tissues are not fully recapitulated in monolayer cultures. On
the other hand, although mouse models provide a much more
physiologically relevant system, they are not cost effective
and many of the human features are not reliably modelled
due to considerable species-specific differences in functions
of FRT. For example, the endometrium of the mouse does not
undergo menstruation and spontaneous decidualisation [104].
3D organoid cultures generated from the FRT, a recent ad-
vancement for this field, provide solutions to many of the
limitations of the available model systems: they can be prop-
agated long-term, function like the tissue of origin and are
relatively cost-effective. Here, we summarise the recently
established organoid systems of the FRT (Fig. 4).
Fallopian tube and ovarian organoids
Various 3D models have been developed for the in vitro culture
of primary human FT epithelium. For example, transwell based
air-liquid interface cultures using a cell culture medium contain-
ing Dulbecco’sModified Eagle’sMedium (DMEM)/Ham’s F12
1:1 supplemented with 2% serum substitute UltroserGwere used
to study FT biology and pathology. Although these cultures re-
capitulated some aspects of the in vivo architecture of the FT
epithelium and consisted of polarised cells of both secretory
and ciliated types, they cannot be propagated long-term [105,
106]. Subsequently, organoids that can be propagated long-
term were derived from human FT that are EpCAM+ and con-
tain both PAX8+ secretory and acetylated-α-tubulin+ ciliated
cells (Fig. 4) [38]. Their long-term propagation is supported by
growth factors that modulateWnt, Notch, EGF, FGF and TGF-β
signalling pathways (Table 1) [38]. Wnt and Notch are essential
for the establishment of human FT organoids and inhibition of
Notch promotes ciliary differentiation [38, 39]. Similarly, in the
mouse oviduct, Wnt/β-catenin signalling is required for epithe-
lial homeostasis and self-renewal of secretory cells [40]. Human
FT organoids are hormonally responsive as the FT in vivo.
Several genes that are thought to play an important role in
fertilisation, including PGR and oviductal glycoprotein 1
(OVGP1), are inversely regulated by E2 and P4 during the men-
strual cycle [38]. With hormonal treatment these were also reg-
ulated in the same way in FT organoids.
Human OSE has been difficult to grow and many attempts
have been made to establish long-term cultures. In an initial
report of 3D cultures of human OSE, primary cells isolated
from normal ovaries were resuspended in a medium contain-
ing 10% serum and cultured on a Matrigel coated well, which
resulted in the formation of spheroids that were positive for
OSE markers including calerectin and cytokeratins (stained
with antibody cocktail KRTAE1) [114]. However, these are
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not long-term cultures. A recent study has established defini-
tive organoids of human OSE (Fig. 4) [107]. FT and OSE
from women with a high risk of ovarian cancer due to
germline mutations in BRCA1/2 genes were used to derive
organoids (Table 1) [107]. OSE organoid lines were
established with > 90% efficiency but they grew more slowly
than the FT-derived organoids. OSE organoids are KRT8+
and show typical folds and invaginations similar to FT
organoids. However, further work is needed to improve
their ability to be propagated long-term. Organoids derived
from murine OSE can be passaged indefinitely under culture
conditions containing Wnt3a, Rspondin-1, Noggin, EGF, nic-
otinamide, hydrocortisone and β-estradiol (Table 1) [110].
Similarly, to the human FT organoids, these are cystic with
mucosal folds and contain both ciliated and secretory cells.
These models show great promise for the study of FT and
OSE biology.
Endometrial organoids
The ability of endometrial epithelium to form 3D structures
in vitro was first described using primary cell isolates grown as
a monolayer on Matrigel in serum-free conditions that spontane-
ously formed 3D glandular-like structures [115]. These tubular
structures contain a central lumen lined by cells with microvilli.
Subsequently, spheroidal cultures of murine endometrial epithe-
lium with polarised, CDH1+ cells surrounding a central lumen
were generated by culturing them in a medium containing EGF,
insulin-transferrin-selenium supplements and Matrigel [116,
117]. A similar spheroidal culturemethodwas used to investigate
the stem cell/progenitor characteristics of SSEA1+ and CDH2+
human endometrial epithelial cells located in the basal layer, in
two different studies [57, 59]. Both SSEA1+ and CDH2+ cells
are capable of forming spheroidal, gland-like structures at higher
efficiency than their negative counterparts. Furthermore,
SSEA1+ cells fromwomenwith endometriosis, a disorder where
endometrial epithelial and stromal cells grow outside the uterine
cavity, also showed higher spheroid forming capacity compared
with normal endometria, providing further evidence for their
stem cell ability [58]. The spheroid assays are a useful method
to investigate proliferative and clonal capacities; however, the
long-term ability of the cultures has not been shown.
Using the approach established by the Clevers lab, endo-
metrial organoids (EO) that can be expanded and cultured
long-termwere established using endometrial tissue from both
human and mice (Fig. 4) [50, 111]. Human EO can be derived
from all stages of the menstrual cycle, including from meno-
pausal and pregnant endometrial tissues (decidua) with near
100% success rate, whilst in mice, establishment of EO is
most efficient when samples are obtained at the estrous phase
[50, 111]. EO from both species have similar morphology and
grow as spheroids with the apical surface of the cells lining the
central lumen. Similar conditions used in other organoids sys-
tems are needed to grow EO. Murine EO are grown in Wnt3a
and Rspondin-1 conditioned medium supplemented with
EGF, FGF-10, Noggin, nicotinamide and TGF-β inhibitor
and can be expanded every 7–10 days for several months
(Table 1) [111]. Human EO grow in similar conditions but
addition of exogenous Wnt is not necessary [50]. There are
different human EO media with the addition or omission of
factors including hepatocyte growth factor (HGF), E2, p38
MAPK inhibitor, prostaglandin E2 (PGE2), β-estradiol and
Wnt activator (CHIR99021) (Table 1) [50, 111, 112]. EO
can be cultured extensively in these media variations but it
Fig. 4 Organoids of normal and
diseased tissues of the human
FRT. Organoid models derived
from normal and pathological
tissues are illustrated. The
different cell types that are present
in the tissue epithelia and the
organoids are shown as columnar
(non-ciliated), secretory, ciliated,
cuboidal and squamous. The
organoids recapitulate cellular
heterogeneity, genetic signature
and key functions of the tissue of
origin
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Table 1 Media components for the derivation and propagation of
organoids from healthy and diseased human and mouse FRT. The
growth factors and inhibitors required for the establishment of organoid
cultures as well as their expansion for at least 10 passages are
summarized. For each region of the FRT, organoids derived from
healthy and pathological tissues are listed
FRT Specie Tissue source Organoid mediuma Reference
Ovary Human Ovarian tissue from prophylactic bilateral
salpingo-oophorectomy (with/without
BRCA1/BRCA2 mutations)
Wnt3a CM, Rspondin-1 CM, Noggin CM,




Human Ovarian carcinoma (low and high grade serous
adenocarcinoma, mucinous adenocarcinoma,
clear cell carcinoma, endometrioid carcinoma,
serous borderline tumour)
Wnt3a CMb, Rspondin-1 CM, Noggin CM,




Human High-grade serous ovarian carcinoma
(primary tumour deposits within
abdominal cavity)
Wnt3a CMc, Rspondin-1 CMc, CHIR99021c,
Nogginc, BMP2c, EGF, FGF10c,
Nicotinamide, SB431542, Y-27632,
[108]
Human Ovarian carcinoma (low and high grade
serous adenocarcinoma, mucinous
adenocarcinoma, clear cell carcinoma)
Rspondin-1 rec/CM, Noggin rec/CM,
EGF, FGF10c, FGF2c, IGF1c, HGFc,
Nicotinamide, A83-01, Y-27632d, NRG1c,
SB203580, β-Estradiol
[109]






Human Anatomically normal FT tissue
(removed for benign gynaecological
diseases)
Wnt3a CM, Rspondin-1 CM, Noggin,
Nicotinamide, EGF, FGF10, Y-27632,
SB431542
[38]
Human FT tissue from prophylactic bilateral
salpingo-oophorectomy (with/without
BRCA1/BRCA2 mutations)
Wnt3a CM, Rspondin-1 CM, Noggin CM,
Nicotinamide, EGF, A83-01, Y-27632
[107]
Mouse FT fimbriae Wnt3a CM, Rspondin-1 rec/CM, Noggin,
EGF, Y-27632e
[110]
Mouse FT tissue Wnt3af, Rspondin-1f, Nogginf, EGF,
FGF10f, SB431542, Y-27632
[39]
Endometrium Human Endometrial biopsies (proliferative,
secretory and postmenopausal phases);
decidual tissue (first trimester
termination samples, 6–9 weeks
gestation from
normal pregnancy)
Rspondin-1, Noggin, EGF, FGF10, HGF,
Nicotinamide, A83-01, Y-27632g
[50]
Human Endometrial biopsies in proliferative
phase (laparoscopy for benign
gynaecological conditions)
Wnt3a CM, Rspondin-1 CM, Noggin,
EGF, FGF10, Nicotinamide, A83-01,
Y-27632d, SB202190, β-Estradiol
[111]
Human Decidua (first trimester termination





Human Endometrial tissue (menstrual,
proliferative, secretory phases)
Rspondin-1 CM, Noggin rec/CM, EGF,
FGF2, FGF10, Nicotinamide, A83-01,
Y-276322d, SB202190, β-Estradiol
[113]
Human Ectopic (stages I–IV) and eutopic
endometrium (proliferative,
secretory phases) from endometriosis
Rspondin-1 CM, Noggin rec/CM, EGF,
FGF2, FGF10, Nicotinamide, A83-01,
Y-276322c, SB202190, β-Estradiol
[113]
Human Endometrial hyperplasia (simple benign,
complex atypia, Lynch syndrome)
Rspondin-1 CM, Noggin rec/CM, EGF,
FGF2, FGF10, Nicotinamide, A83-01,
Y-276322d, SB202190, β-Estradiol
[113]
Human Endometrioid, clear cell, serous
endometrial carcinoma (grades I–III)
Rspondin-1 CM, Noggin rec/CM, EGF,
IGF1, HGF, Nicotinamide, A83-01,
Y-27632d, SB202190, β Estradiol
[113]
Mouse Uterine horns (estrous phase) Wnt3a CM, Rspondin-1 CM, Noggin,
EGF, FGF10, Nicotinamide, A83-01,
Y-27632d
[111]
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remains to be investigated whether the cellular composition
and cell states of the organoids are different.
EO faithfully recapitulate the morphological and molec-
ular features of endometrial glands in vivo. A comparison
by microarray of original glandular fragments with
organoids from the same patient sample shows high simi-
larity in their gene expression profiles; for example, genes
of the secretory lineage and of murine endometrial glands,
PAX8, SOX17 and FOXA2, are uniformly expressed in hu-
man EO [50]. EO can functionally respond to ovarian hor-
mones E2 and P4, similar to in vivo epithelium by produc-
ing glandular milk proteins, osteopontin and glycodelin,
and forming ciliated cells [50]. They also have clonogenic
ability as organoids can be generated from a small propor-
tion of cells (between 1 and 3%) by limiting dilution assay
[50]. These clonal cultures are bipotential and can differ-
entiate into both secretory and ciliated cells providing an
opportunity to study the cell lineage relationships and the
regenerative ability of endometrial epithelial cells.
Concomitant NOTCH inhibition and E2 signalling in
directing the differentiation towards the ciliated cells were
demonstrated using EO [112]. Functional studies using EO
have also revealed a potential role of the mechanosensitive
ion channel, PIEZO1, in promoting implantation [118].
A major goal in the field is to identify stem cells of the
endometrium. In mice, Axin2+ cells that reside in the basal
glands are able to give rise to fully functional endometrial
organoids that can generate both ciliated and glandular line-
ages [60]. The identity of endometrial stem/progenitor cells in
the human endometrium remains to be established but this
work paves the way to investigate whether a similar popula-
tion exists using human EO. Furthermore, applications of re-
cent technologies including single-cell RNA-sequencing and
spatial transcriptomics will allow the investigation of potential
markers to isolate and localise these cells in vivo [119,
120,121, 122].
Cervical organoids
Recently, long-term, expandable organoidmodels of the squa-
mous stratified ectocervix and columnar endocervix have
been developed (Fig. 4) [78]. In line with the distinct molec-
ular microenvironment that underlies these two epithelial
types in vivo, the ecto- and endocervical organoids also de-
pend on distinct growth factor combinations for their forma-
tion and long-term expansion [78]. In vitro recapitulation of
organoids from human and mouse ectocervix depends on
EGF, FGF-10, hydrocortisone, active BMP signalling and in-
hibition of TGF-β and ROCK (Table 1). Presence of Wnt
signalling agonists (Wnt3a and Rspondin-1) are inhibitory
for the development of human ectocervical organoids [78].
Additionally, forskolin, an inducer of cyclic adenosine 3′,5′-
cyclic monophosphate (AMP), further supports the long-term
propagation of these organoids. These organoids from mouse
and human are similar and mimic the in vivo ectocervical
epithelial tissue architecture [78]. They consist of multilayered
KRT5+ epithelia with basal proliferative TP63+ cells
superimposed by parabasal layers that have low TP63 expres-
sion and with more differentiated cells towards the inner lu-
men [78]. Differentiation of ectocervical organoids is
Table 1 (continued)
FRT Specie Tissue source Organoid mediuma Reference




Mouse Endocervical tissue Wnt3a CM, Rspondin-1 CM, Noggin, EGF,
FGF10, Nicotinamide, Y-27633, SB431542
[78]
Mouse Ectocervical tissue Noggin, EGF, FGF10, Nicotinamide, SB431542,
Y-27632
[78]
Vagina Mouse Vaginal tissue EGF, A83-01, Y-27632, Ultraserum-G [96]
FT fallopian tube, CM conditioned medium, rec recombinant, EGF epidermal growth factor, FGF fibroblast growth factor, HGF hepatocyte growth
factor, A83-01 TGFβ receptor inhibitor, NRG1 neuregulin 1, SB431542 TGFβ receptor inhibitor, SB202190 p38 MAPK inhibitor, SB203580 p38
MAPK inhibitor, Y-27632 ROCK inhibitor, CHIR99021 GSK-3 inhibitor, PGE2 prostaglandin E2
a Excluding basal medium components (i.e. advancedDMEM/F12, N2, B27, insulin-transferrin-selenium (ITS), Glutamax, N-acetylcysteine, antibiotics,
HEPES); all factors are recombinant if not designated ‘CM’
b Some tumour organoids require Wnt3a CM
c Supplementation/omission of these factors depends on the sample
d Supplementation only for initiation of organoid cultures or after passaging
e Supplement for recovery of organoids after thawing
f Not essential for long-term culture but results in more mature organoids
g Supplement for derivation and expansion of clonal organoid cultures or for recovery of organoids after thawing
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dependent on Notch signalling as its inhibition leads to a fail-
ure in stratification, resulting in a TP63+ monolayer [78].
Using similar growth conditions, primary ectocervical epithe-
lium can be grown in a transwell based air-liquid interface
culture system so that the differentiated epithelial layers are
amenable to pathogens or drug treatments, mimicking the
in vivo situation [123].
Endocervical organoids have been generated from hu-
man and mouse endocervical tissue [78]. Maintenance of
these cultures requires Wnt3a and Rspondin-1, EGF, FGF-
10, active BMP signalling and inhibitors of TGF-β and
ROCK (Table 1) [78]. They are composed of a monolayer
of columnar, polarised cells with sporadically proliferating
cells recapitulating the in vivo architecture of the
endocervix [78]. Molecular characteristics include expres-
sion of KRT8, KRT7, KRT18, arginase 2 (ARG2) and gua-
nine deaminase (GDA) [78]. Based on cytokeratin expres-
sion profiles visualised by immunohistology, small cuboi-
dal subcolumnar reserve cells in the TZ and endocervix are
the likely multipotent progenitors that can regenerate both
columnar and squamous stratified cervical epithelia. By
using murine organoids and lineage tracing in vivo, it is
clear that the ecto- (KRT5+) and endocervical (KRT8+)
epithelia are derived from two distinct lineages that merge
at SCJ [78]. Furthermore, in agreement with these studies,
in the absence of Wnt3a and Rspondin-1, human organoid
models recapitulate the development of squamous metapla-
sia from the endocervical KRT5+ reserve cells that are dis-
tinct fromKRT8+ glandular cell lineage [78]. Thus, cervical
organoids are surrogate models for understanding cervical
homeostasis, as their responses, for instance to Wnt growth
factors, recapitulate the dynamics of metaplasia at the SCJ
in vivo.
Vaginal organoids
The culture and long-term maintenance of murine vaginal
organoids require 2% Ultraserum-G, EGF, TGF-β and
ROCK inhibitors (Table 1) [96]. Human vaginal organoids
have not been described yet. Organoids from mice have a
stratified squamous epitheliumwith TP63+ cells at the periph-
ery, mimicking the architecture of vaginal tissue in vivo.
Vaginal organoids depend on cell-autonomousWnt signalling
for their proliferation and differentiation [96]. Treatment with
IWP2, a small-molecule inhibitor of Wnt signalling, or condi-
tional ablation of β-catenin, resulted in decreased size and
formation of organoids [96]. Although increasing Wnt in the
medium improved the growth of organoids, high concentra-
tions had the opposite effect, suggesting that fine regulation of
Wnt activation regulates vaginal epithelial behaviour. This
model will be essential for the study of the mechanisms un-
derlying the regeneration and homeostasis of the vaginal
epithelium.
Organoid systems to model diseases
of the female reproductive tract
With the recent surge of reports of organoids from the FRT,
studies are appearing describing their use in modelling a range
of pathological conditions. Here, we review the diseases of the
FRT that have been modelled to date (Fig. 4).
Endometriosis
Endometriosis occurs when endometrial tissue is found outside
the mucosal lining of the uterine cavity. These endometriotic
lesions are found in several sites including the ovaries, pelvic
peritoneum and small and large bowel. Endometriosis affects ~
10% of women of reproductive age [124]. A genetic contribu-
tion is likely but the etiology, pathogenesis and underlying
biology of endometriosis remain essentially unknown
[125–128]. Several sources of endometriotic lesions have been
suggested including retrograde menstruation of endometrial
stem/progenitor populations, metaplasia of peritoneal mesothe-
lium and lymphatic and vascular metastasis of endometrial cells
[129–132]. The ectopic endometrial lesions contain glands,
stroma as well as uterine natural killer cells. They are E2 re-
sponsive and invasive, causing debilitating pelvic pain and
chronic inflammation [128]. Depending on the number, depth
and location of lesions, endometriosis can be staged from grade
I (minimal) to grade IV (severe) [133, 134].
Medical management consists in reducing E2 production
by administration of oral contraceptives, progestogens, GnRH
agoni s t s or androgen s te ro ids [135] . However ,
hormonal treatment is only suitable for women who are not
planning to conceive and there are considerable side effects. If
medical intervention is unsuccessful, removal of the
endometriotic lesions by surgery is an option but success de-
pends on the number, location and stage of diseases and re-
currence occurs in 30–50% of women [136, 137].
Hysterectomy and/or oophorectomy reduces recurrence but
this may not be an option in women of reproductive age.
Endometriosis is not only a huge burden on the quality of life,
it is also associated with infertility as well as higher suscepti-
bility to ovarian and breast cancer [138].
A recent study holds great promise for the study of endome-
triosis. A biobank of EO was established from endometriotic
lesions from different clinical stages, including paired
organoids from ectopic (ECT) and eutopic endometrium
(EUT) from the same patient (N = 15) [113]. These organoids
are grown in a medium based on their previous endometrial
organoid medium but with addition of FGF2 and omission of
Wnt3a (Table 1) [111, 113]. The morphology of the ECT
organoid differed from EO and EUT organoids as they show
hyperplastic epithelium (Fig. 4). ECT organoids maintain ex-
pression of epithelial markers CDH1 and cytokeratin as well as
hormone receptors, E2 receptor α (ESR1) and P4 receptor
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(PGR). Despite the variability of gene expression profiles with-
in the ECT organoid group, the RNA sequencing comparison
to EO revealed alterations in PI3K-AKT, Wnt and hormonal
responsive signalling pathways. Furthermore, characteristic
known transcripts of endometriosis (aberrant expression of ma-
trix metalloproteinase (MMP), integrins and the production of
inflammatory cytokines IL-1β and IL-8) were also higher in
ECT organoids [113, 139–141]. The inherent ability of human
ECT organoids to establish and form ectopic endometriotic
lesions was demonstrated by injection into murine intraperito-
neal cavities [113]. However, it is important to note that stromal
and immune populations, which are essential components of
endometriotic lesions, are not recapitulated in this model. The
organoid model of endometriosis recapitulates key epithelial
features of the disease and will allow investigation of signalling
pathways and genes that may drive the pathology, essential
information for the discovery of new non-hormonal therapies.
Endometrial carcinoma
Endometrial carcinoma (EC) is the most common
gynaecological malignancy, the fifth most common cancer
in women, and has an increasing prevalence [142]. Risk fac-
tors include endogenous and exogenous exposure to
oestrogens, use of tamoxifen, nulliparity, early-onset menar-
che and late-onset menopause. Traditionally, EC has been
classified into two main subtypes based on histological char-
acteristics, hormone receptor expression and grade:
endometrioid (type I) and serous (type II) tumours [143].
Type I is correlated with excess oestrogen, obesity, diploid
tumour cells, hormone receptor positivity and a good out-
come. Type II is common in older women and has a poor
prognosis; there are abundant aneuploid cells and no expres-
sion of hormone receptors. The most frequent alterations in
type I EC are: mutations in the phosphatidylinositol-4,5-
bisphosphate 3-kinase (PIK3CA) pathway, with 90% of tu-
mours showing loss of phosphatase and tensin homologue
(PTEN) [144]; mutations in KRAS found in 20% of tumours
[145]; mutations in fibroblast growth factor receptor 2
(FGFR2) in 12% of tumours [146]; amplification of human
epidermal growth factor receptor 2 (HER-2) in some subtypes
[147]; loss of DNA mismatch repair (MMR) proteins (found
in hereditary Lynch syndrome) [148]. Type II is more diverse
with a range of histological subtypes; some tumours show
features of serous ovarian carcinoma [149]. Thus, it is increas-
ingly clear that when the pathology is combined with molec-
ular and genetic features, there is a range of distinct EC sub-
types [150, 151].
To investigate the cell-of-origin of endometrial hyperplasia
and adenocarcinomas, two pathways commonly perturbed in
human EC (PI3K and Wnt) were introduced into a mouse
model that allows the tracing of Axin2+ stem cells [60].
After tamoxifen induction (which mimics exposure to
oestrogen), carcinomas were indeed found throughout the
uterus. Furthermore, these were a result of clonal expansion
of mutant Axin2+ cells, suggesting that upon oncogenic trans-
formation, Axin2+ cells may be responsible for the develop-
ment of EC. Indeed, the enhanced growth capacity of these
cells was demonstrated by their ability to generate higher
numbers of organoids than wild type, and they presented typ-
ical features of tumouroids with branched morphology and
loss of the lumen [60]. Furthermore, when transplanted into
chicken embryo chorionic allantois membranes, mutant
Axin2+ cells were able to form organoids even without the
presence of niche factors Wnt and Rspondin, in contrast to
wild-type cells. AXIN2 is also expressed in human endometri-
al glands [60]. Studies have revealed the clonal nature of en-
dometrial glands in humans which frequently harbour driver
mutations in cancer genes [152–154]. A similar forward ge-
netic approach using human endometrial organoids may help
elucidate the etiology of EC.
Several studies have reported the derivation of organoids
from EC (Fig. 4) [50, 113, 155]. In the first proof-of-principle
experiment, organoids were derived from endometrial adeno-
carcinomas, together with the adjacent normal endometrium
using the same expansion medium for EO (Table 1) [50]. The
architecture of the tumour organoids resembles the primary
tumour; there is a multi-layered epithelium instead of the nor-
mal simple columnar epithelium, mitoses are frequent and
isolated cells are present in the surrounding Matrigel. EC
organoids were then generated from hysterectomy specimens
from type I EC at different stages (N = 15) [155]. The disso-
ciated malignant cells were embedded into basement mem-
brane extract (BME) and grown in organoid medium contain-
ing nicotinamide, TGF-β inhibitor, p38MAPK inhibitor, Rho
kinase inhibitor and 17-β estradiol loosely based on organoid
medium used for colonic carcinoma organoids [156]. The ad-
dition of the more commonly used organoid growth factors,
EGF, FGF2, FGF-10, PGE2, Noggin, Rspondin-1 andWnt3a,
was not required for derivation although they might be needed
for long-term growth. Morphological and histological charac-
teristics like the expression of ESR1 and PGR reflected those
of the original tumours. Several drugs were tested at the der-
ivation stage to monitor effects on organoid establishment.
This resulted in the identification of a new therapeutic
STAT3 inhibitor, which showed potent growth inhibition of
established 10 EC organoid lines [155].
The remarkable ability of the organoid method to generate
cellular structures that faithfully recapitulate the genomic and
transcriptomic features of the tumour is demonstrated in a
recent study in which EO were derived from different stages
of EC (N = 30), including endometrial hyperplasia, the pre-
malignant state of EC [113]. Organoids were generated from
different types of endometrial hyperplasia (benign, complex
atypia and polyp) at 70% efficiency and could be grown long-
term. These organoids showed a disorganised epithelium,
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though a central lumen was present. Specific genetic alter-
ations found in the primary lesions, such as absence of TP53
and mutations in the MMR genes from the Lynch syndrome
patients, were maintained in these organoids [113]. The deri-
vation efficiency of EC organoids was much lower (20%) and
they showed limited ability to propagate, with non-cancerous
endometrial organoids overtaking the cultures. However,
modification of their organoid medium with the removal of
p38 MAPK inhibitor and addition of HGF, IGF1 and lipids
enhanced tumour organoid formation, improved their ability
to propagate and increased clonogenic ability (Table 1). The
organoid lines had different morphologies with high-grade
tumours displaying more dense structures with a lack of lu-
men. The EC organoids captured both the genetic, histological
features and transcriptional similarity to the tumour of origin
[113]. For example, using comparative genomic hybridisation
or low-coverage whole-genome sequencing, the organoids
were shown to retain a large portion of somatic copy number
aberration (SCNA) found in the tumours, even with long-term
passaging. A comparative transcriptomic analysis between
EO, organoids derived from endometrial hyperplasia and EC
showed over representation of PI3K-AKT signalling pathway
as well as higher expression of genes involved in epithelial-
mesenchymal transition [113].
Drugs targeting the molecular and genetic pathways altered
in individual tumours have not yet been introduced on a rou-
tine basis and current treatment is total hysterectomy and use
of adjuvant treatment (radiotherapy or chemotherapy) in
women with extra-uter ine or high-r isk tumours.
Identification of driver mutations within tumours that can be
targeted specifically, for example trastuzumab for the treat-
ment of breast cancer with amplification of the gene encoding
epidermal growth factor receptor HER2, could be the way
forward for EC [157]. However, the use of gene-drug associ-
ations to identify therapeutic treatments is not always infor-
mative as the actual number of targetable mutations that result
in an effective therapy is relatively low [158]. Thus, to have a
platform to screen for differential drug sensitivity and identify
an effective treatment of ECwould be of great benefit. Using a
biobank of EC organoids, a small drug screen has shown the
potential of this model for patient-specific targeted therapy.
Five different EC organoid lines (derived from grades I to
III) were grown in the presence of several chemotherapeutic
agents (5FU, carboplatin, doxorubicin, everolimus, paclitaxel)
and their viability was measured using the XTT (tetrazolium
dye) cell proliferation assay [113]. The organoids showed dif-
ferent responses to the drugs, showing promise for
personalised medicine approaches.
Ovarian carcinoma
Ovarian carcinoma (OC) is a heterogeneous disease
encompassing a wide diversity of tumour subtypes with distinct
genetic and pathological characteristics. It affects ~ 225,500
women worldwide every year and is the 7th most common
cancer-related death in women [142]. Risk factors include ge-
netic factors, age and infertility [159]. The late diagnosis, ag-
gressive nature and lack of effective treatment and screening
strategies are responsible for high mortality rates with 5-year
overall survival at 25% for patients with advanced stages of the
disease [159]. OC can be categorised into three subgroups:
border-line tumours, type I which includes low-grade serous
carcinoma, clear-cell carcinoma, mucinous carcinoma and
low-grade endometrioid carcinoma and type II high-grade se-
rous carcinoma (HGSC) and high-grade endometrioid carcino-
ma [159, 160]. Although different mutations have been associ-
ated with some OC subtypes, the molecular mechanisms driv-
ing the pathogenesis remains unknown.
Given their ability to represent the heterogeneity of the tu-
mour, the OC organoids hold great promise to study the biology
and pathogenesis in order to improve clinical management and
treatment of patients. In the first report, organoids were derived
from HGSC, the highest grade and most common form of ovar-
ian cancer (Fig. 4) [161]. Primary, metastatic or recurrent tu-
mours were enzymatically digested and grown in Matrigel using
a medium containing Rspondin-1, Noggin, EGF, FGF2 and 10,
nicotinamide, PGE2 and inhibitors of TGF-β and p38 MAPK
signalling (Table 1). The organoids showed key morphological
features of HGSC like nuclear pleomorphism and disorganised
epithelium but could only be expanded short-term.Amore recent
study reported further improvement of the HGSC organoid sys-
tem and 15 organoid lines were established with 30% efficiency
from advancedHGSCdeposits [108]. HGSC organoids require a
substantially modified growth medium in keeping with the mod-
ification of the niche factors seen in other tumour organoids
[162]. EGF was the only indispensable component and Wnt
activation was detrimental for HGSC organoid growth [108].
This optimised OC medium that consists of EGF, BMP2, nico-
tinamide and inhibitors of ROCK and TGF-β allows long-term
culture of HGSC organoids that maintain key histological and
morphological characteristics of the tumours of origin (Table 1)
[108]. Organoids were also derived from the whole spectrum of
OC subtypes and additional compounds during organoid deriva-
tion identified hydrocortisone, forskolin and NRG1 as beneficial,
which was also confirmed by another study (Table 1) [107, 109].
Fifty-six organoid lines were derived at 65% efficiency; 85% of
the lines recovered after cryopreservation, a prerequisite for the
creation of a bio-bank [107].
The diverse morphologies characteristic of OC are typical of
the range of organoid structures seen. There is a close correlation
between the histological and molecular features of the organoids
with the original tumour samples [107–109]. Thus, organoids of
ovarian serous carcinomas are PAX8+ with a similar pattern of
TP53 expression. Somatic mutations of BRAF and KRAS are
frequent in some tumour subtypes and are retained in the corre-
sponding organoids even after long-term passaging. The same is
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true for global epigenetic profiles of DNA methylation.
Transcriptomic profiles of 35 OC organoid lines cluster with
the original tumour samples and not with unrelated organoids
[107]. Furthermore, this analysis revealed interesting biological
insights into similarities between tumour types. The authors
found that one type of pre-malignant lesion clusters with a spe-
cific subtype of OC, shedding light on precursors of invasive
carcinomas. Thus, these models present an opportunity to study
the pathogenesis of OC.
The great diversity of types of OCmeans that drug sensitivity
tests are particularly valuable for these tumours. Twenty-one
HGSC and non-HGSC organoid lines were treated with a panel
of drugs and responses were measured by dose-response curves
based on viability [107]. The majority of organoid lines
responded to known treatments. For example, the genetic fea-
tures of HGSC render the tumours sensitive to DNA damage,
and in fact, a large proportion of HGSC organoids were sensitive
to carboplatin/paclitaxel drugs whilst others were less so. This
means new treatments can be tested on these non-responsive
tumours in vitro like non-cisplatin compounds, including inhib-
itors of the PI3K/AKT/mTOR pathway, Poly(ADP-Ribose)
Polymerase 1 (PARP), the tyrosine kinase, Wee1 and
gemcitabine. There are differences in drug sensitivity evenwithin
the same tumour type and organoids derived from recurrent
chemoresistant tumours. To provide proof that this drug sensitiv-
ity is maintained in vivo, when HGSC organoids sensitive to
gemcitabine, a nucleoside analogue, were transplanted into mice,
treatment with gemcitabine reduced tumour growth [107]. Thus,
the OC organoids would allow pre-clinical functional assessment
of the tumour to the drug.
Studies using mouse models and single-cell analysis of hu-
man fallopian tube cells suggest that HGSC can originate from
the fallopian tube epithelium [41, 44, 163–166]. However, dis-
tinct subtypes of HSGC can also originate from the ovarian
surface epithelium [110]. Recently, three commonly mutated
genes TP53, RB1 and PTEN found in HGSC were knocked
down by short hairpin RNA (shRNA) in human FT organoids
to model the FT-derived HGSC development [108]. Several
changes suggest pro-carcinogenic progression in these organoids
including apical-basal polarity and functional responses to the
altered targeted loci, for example the resistance to apoptosis by
Nutlin-3A, due to loss of TP53. However, they can still undergo
differentiation to ciliated cells indicating that they have not fully
transformed. When grown in the optimised ovarian carcinoma
medium, stem cell markers, CD133 and SOX2, increase and
differentiation genes, PGR and FOXJ1, decrease suggesting that
in the context of these genetic changes, the absence of Wnt
maintains their altered proliferative state.
Cervical carcinoma
Carcinomas of the cervix are the leading gynaecological can-
cer of women with more than half a million cases diagnosed
and 300,000 deaths worldwide each year [142]. Cervical car-
cinoma occurs as two major, histologically distinct types: ad-
enocarcinomas (ADC) and squamous cell carcinomas (SCC),
constituting 9% and 90% of all the cervical cancers, respec-
tively. Failure of early detection is the main cause of death;
otherwise, the disease is treatable with surgery or chemo-ra-
diation, or a combination of both. Persistent HPV infections
with particular HPV subtypes are the etiological agent in vir-
tually all cases. Prophylactic vaccines against these carcino-
genic HPV types are available; however, the number of people
receiving these remains low and new therapeutic approaches
are needed [167].
The spectrum of histopathological changes seen in HPV
infection that leads to cervical carcinoma reveals how the
disease develops. There is dysplasia of squamous epithelium
and the proportion of these cells present determines the grade
of the dysplasia (cervical intraepithelial neoplasia, CIN) [168].
CIN-1 (low-grade) is mild l dysplasia that can regress; it is
confined to the lower basal third of the epithelium. CIN-2
(moderate dysplasia affecting the basal two-thirds) and CIN-
3 (high-grade or carcinoma-in situ where the entire thickness
of the epithelium is dysplastic) can both progress to invasive
carcinomas when the basement membrane is breached. The
molecular mechanisms HPV uses to transform cervical epi-
thelial cells are known [169]. HPV early genes, E6 and E7,
integrate into the host genome leading to a persistent infection
that disrupts signalling cascades within the host cell.
Hyperproliferation and genomic instability are promoted by
E6-dependent degradation of TP53 and the release of the tran-
scription factor, E2F from retinoblastoma protein (RB1) by E7
[170, 171]. Extensive characterisation of genomic alterations
in large cohorts has been undertaken. In 228 primary cervical
carcinomas, APOBEC mutational signatures and novel muta-
tions in SHKBP1, ERBB3, CASP8,HLA-A and TGFBR2were
revealed [172]. Amplifications in immune targets CD274
(PD-L1) and PDCD1LG2 (PD-L2) and the BCAR4 long
non-coding RNAwere also observed. Not all cervical tumours
are associated with HPV infections and therefore will not be
prevented by vaccination. A unique set of these rare HPV-
negative cervical carcinomas that resemble endometrial tu-
mours have higher frequencies of KRAS, ARID1A and PTEN
mutations.
The nature of the progenitor cells giving rise to ADC and
SCC is controversial but adult stem cells can be a source of
tumours [173]. They may arise from undifferentiated fetal
reserve cells, transdifferentiation of cells of the TZ or even
stromal cells [174, 175]. A transcriptomic comparison of cer-
vical organoids with samples of cervical carcinomas revealed
shared expression profiles between endocervical organoids
with ADC and ectocervical organoids with SCC, suggesting
that they may originate from two distinct lineages [78]. Thus,
these organoids provide a model system to study carcinogen-
esis and to identify specific therapeutic targets for each
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lineage. Patient-derived cervical organoids that represent het-
erogeneity of the tumour cells are needed to test potential
therapeutic targets for cervical carcinomas. There are efforts
to establish growth conditions for in vitro culturing of
organoids of cervical carcinomas. Indeed, organoids from a
rare subtype of cervical cancer, clear cell carcinoma, have
been established and can be propagated for 6 months in a
medium containing EGF, Rspondin-1, Noggin, ROCK inhib-
itor and Jagged-1 [176]. Progress in the development of these
in vitro tools from all the subtypes of the cervical cancers
would be invaluable for drug and immunotherapy testing, as
well as for personalised medicine.
Infection of the FRT
The vagina and cervix are colonised by diverse commensal
microorganisms, microbiota, that maintain a symbiotic rela-
tionship with the host. These can be outnumbered by patho-
gens resulting in infection that can ascend to the upper FRT.
The most prevalent pathogens include Treponema pallidum
(syphilis), Neisseria gonorrhoeae, Chlamydia trachomatis,
Trichomonas vaginalis, HPV and herpes simplex virus
(HSV) [177]. There has been progress in understanding the
interactions between the host, the native microbiota and the
invading pathogens, and how these affect outcome. Most ex-
perimental models to study host-pathogen interactions have
used genetically unstable 2D cancer cell lines or immortalised
cell lines adapted to in vitro cell culture. Although murine
models have also contributed to understanding the human
situation, mice have different microbiota and have coevolved
with different sets of pathogens and the patterns of the disease
vary between the two species [178].
Organoids are an excellent alternative to study host-
pathogen interactions because the molecular mechanisms
mimic normal human physiology. Infection of 3D transwell-
based air liquid interface cultures (organotypic cultures) of
human squamous ectocervical epithelium demonstrated the
ability of Chlamydia to infect differentiated luminal cells with
progression towards the basal stem cell compartment caused
by disruption of epithelial integrity and induction of epithelial
to mesenchymal transition [123]. Chlamydia increases hyper-
methylation of DNA, which is an indicator of accelerated
molecular ageing and might be a contributing factor in the
development of tubal pathologies, including the initiation of
HGSC. A recent study modelled chronic chlamydia infections
using FT organoids and the resulting impact on host DNA
methylation [179]. The infected organoids showed higher
stemness potential with reduced differentiation mediated by
activation leukaemia inhibitory factor (LIF) signalling. HPV
fail to replicate in transformed 2D cell lines as they require all
stages of epithelial differentiation to replicate and complete
their life cycle. Squamous stratified ectocervical organoids
can facilitate HPV replication as well as modelling the native
viral infection and the long-term impact on the tissue.
Although co-infection of FRT is often associated with disease
severity for example, HPV and Chlamydia co-infections are
linked to increased progression of cervical carcinoma, molec-
ular mechanisms of such co-infections are rarely investigated
[87, 88]. Additionally, organoids would allow greater flexibil-
ity for manipulation and experimental design to unravel the
molecular changes induced by infection. Thus, there is great
potential in using the FRT organoids for research into infec-
tions of the FRT to model dynamics of host-microbiome in-
teractions, alterations in epithelial homeostasis and repair and
progression of pathological changes (Fig. 5).
Future development and applications of FRT
organoids
Genome editing of FRT organoids using CRISPR-Cas9
Organoid technology is a powerful tool to study tissues
in vitro due to its amenability to a range of downstream appli-
cations including genome editing. Genetic manipulation of
cell lines has been an essential tool to investigate gene func-
tion, to immortalise primary cells and to fluorescently label
proteins. The discovery and application of the CRISPR (clus-
tered regularly interspaced short palindromic repeats)/Cas9
system have revolutionised the way genome editing can be
achieved due to its high specificity, efficiency in the targeting
mechanism and simplicity of use. CRISPR/Cas9 is a compo-
nent of the bacterial adaptive immune system against bacte-
riophages [180–183]. In genome engineering applications in
mammalian cells, the CRISPR/Cas9 system is exploited to gen-
erate double-strand breaks in a specific region of interest [184,
185]. This is achieved by a small guide RNA (gRNA), homol-
ogous to the sequence of interest, which directs the Cas9 endo-
nuclease to the target site where it cleaves the DNA. The cell
repairs this double-strand break either by the error-prone non-
homologous end joining (NHEJ) pathway that often results in
mutations or by homology-directed repair (HDR) in the pres-
ence of a DNA repair template. There are now many variations
of this technique that allow the selective activation or repression
of gene expression, site-specific epigenetic regulation and
genome-wide screens (reviewed in [186, 187]).
Genome editing has been achieved in many different
organoid models and is being used to gain insight into tissue
biology and disease from investigating the correction of muta-
tions to the role of driver mutations in cancer progression
[188–190]. For organoids of the FRT, CRISPR/Cas9 has been
applied to FT organoids to study the effects of TP53 and RB1
knockout on the development of ovarian carcinoma [107].
Using a similar forward genetics approach, the progression of
other FRT cancers can be studied by introducing driver muta-
tions. For example, progression of EC can be modelled by
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introducing sequential mutations in PTEN, KRAS and FGF2 or
ERBB2 in EO and investigating the pro-carcinogenic changes
through gene expression profiling and genome sequencing.
Emerging studies have shown how FRT organoids can support
infections as well as recapitulating chronic infections. For in-
stance, chronic infection of FT organoids with Chlamydia
trachomatis revealed altered tissue homeostasis and epigenetics
[179]. Furthermore, investigation of host-pathogen interactions
in combination with CRISPR/Cas9 will allow the identification
of host factors involved in the response to infection and genes
that may be involved in the malignant transformation of cells.
The application of CRISPR/Cas9 technology on FRT
organoids is clearly a powerful approach to address many ques-
tions in the field of reproduction (Fig. 5). However, as for all
targeting approaches, careful validation of the genome-edited
organoids must be performed. Furthermore, the efficiency of
targeting can be an issue for certain organoid types but new
tools are becoming available to overcome these limitations
(reviewed in [191]).
Personalised medicine
Personalised medicine is a therapeutic strategy specifically di-
rected to individual patients and the unique genomic and path-
ological features of the disease [192]. Many disorders of the
FRT are heterogeneous and the ‘one-size-fits-all’ approach is
not always effective. However, personalised approaches have
been difficult to implement because of the lack of techniques to
culture and propagate diseased cells that maintain their cellular
composition and behaviour in vitro. The organoid technique
can overcome these limitations and recent advancements have
shown great promise for personalised medicine approaches to
be adopted in the clinic. As discussed earlier, organoids derived
from EC and OC are already paving the way for personalised
medicine in this field by allowing the propagation of the tumour
whilst retaining its cellular heterogeneity on which to perform
drug screening to identify effective combination of treatments
(Fig. 5) [107, 113]. The ability to cryopreserve FRT organoids
provides the added benefit that they can be bio-banked and used
for pre-clinical drug screening.
Another area where personalised medicine can make an
impact is in assisted reproduction techniques (ART).
Although great advancements have been made since the birth
of the first in vitro fertilisation (IVF) baby in 1988, currently
60–90% of IVF attempts with a transfer of high quality em-
bryos are unsuccessful resulting in either failure of implanta-
tion or miscarriage (loss of pregnancy within 20-week gesta-
tion) [193, 194]. These conditions are distressing for the cou-
ples and are also a financial burden.
An important underlying issue contributing to IVF failure is
the need to synchronise embryonic development with endome-
trial receptivity [195, 196]. The ‘window of implantation’ (WOI)
is at the mid secretory phase when decidualisation commences
and there is maximal receptivity. Based on histological studies,
this is between (LH, day of LH peak/ovulation) + 6 and LH+ 10
in a natural cycle [197]. Compared with normal endometrium at
the time of implantation, some IVF patients show signs of pre-
mature decidualisation and dyssynchronous differentiation of the
Fig. 5 Future applications of organoids of the FRT. Organoids of the
FRT are derived from biopsies and can be used to study tissue biology,
cell-cell interactions, host-pathogen interactions and disease. Tissue en-
gineering methods combine organoids with other cell types to develop
more tissue-like models that include non-epithelial cells. Organoids de-
rived from pathological tissues are useful for drug screening for
personalised medicine
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glands and stroma [198–200]. Although the changes throughout
the cycle in expression of integrins, secretory products and sig-
nalling molecules like LIF have been extensively described, the
mechanisms regulating receptivity are still unknown [197, 201].
There are still no robust markers to predict the WOI to optimise
the timing of embryo transfer. Using EO, the hormonal regimes
can be tested to identify optimal protocols for endometrial
decidualisation. Furthermore, there is great variation of the men-
strual cycle timing between women, so the development of
personalised protocols will be of great benefit [202]. However,
in order for patient-specific EO to be routinely used as a
personalised system in the clinic, development of non-invasive
methods to obtain tissue is needed. Currently, biopsies are taken,
not ideal for repeated sample recovery from the same patient.
Infertility has diverse causes (dysfunction of the ovaries and
FT, lesions in the uterus like fibroids or bicornuate uterus, cervi-
cal stenosis or poor cervical mucus, squamification of
endocervical canal) but is often ‘unexplained’ [203]. These pa-
tients may also benefit by deriving organoids for a personalised
approach to identify the underlying problems.
Bioengineering and FRT organoids
Like all in vitro models, organoid systems have limitations
and there are still numerous challenges to overcome. An ob-
vious example is the ECM used, generally the commercially
available Matrigel, Cultrex, Geltrex or BME, produced by
extracting the gelatinous protein mixture from murine
Engelbreth-Holm-Swarm sarcomas [204]. Because they are
extracted from tumours grown in vivo, there is considerable
batch-to-batch variation in growth factors present, composi-
tion of ECM and stiffness of the gel that have effects on cell
behaviour [205, 206]. Generation of chemically defined and
reproducible hydrogels are clearly needed and these will also
reduce costs and use of animals. Furthermore, to use
organoids for transplantation, avoidance of ECM derived
from animals that might be immunogenic and carry pathogens
is essential. Intestinal organoids can now be grown in synthet-
ic hydrogels with known concentrations of ECM components,
collagen and laminin, or the use of short RGD peptides, the
adhesion motif for integrins [207–209]. Such studies are be-
ginning to be established also for FRT organoids [210]. It is
clear that the ECM composition and stiffness differ through-
out the FRT and this must also be taken into account. Indeed,
endometrial stiffness varies across the cycle and in pregnancy
[211]. More information about the normal composition and
stiffness of the ECM in the whole FRTwill allow introduction
of tailored synthetic matrices for the different organoid types.
Tissue-derived organoids are composed of epithelial pop-
ulations and lack stromal, immune and nerve cells as well as
blood vessels. Although this reductionist approach is an ad-
vantage for the study of epithelial behaviour, it is a limitation
when investigating mucosal function in vivo that may be
controlled through cell-cell interactions. For example, the
transition of the squamo-columnar epithelium of cervix is
controlled by opposing Wnt signals provided by the underly-
ing stromal tissue and alteration to these signals reshape the
epithelial homeostasis including metaplastic adaptations [78].
Increased Wnt antagonists in the endocervix lined
by columnar epithelium and uterus promote the development
of preneoplastic squamous metaplasia [78]. Endometrial
stromal-epithelial interactions are particularly important in
the response to ovarian hormones when stromal cells respond
to P4 by secreting growth factors and cytokines (e.g. prolactin,
IGFBP-1, IL-11) that stimulate the differentiation of epithelial
cells [65, 66]. Studying these interactions in co-culture models
of endometriosis where the stromal component probably plays
a key role in driving pathogenesis will be important [103,
212–214]. Introduction of immune and stromal cells to
organoid models will allow investigation of their roles in tis-
sue homeostasis and function as well as infections with chla-
mydia, gonorrhoea, tuberculosis or HPV. In addition, to mod-
el the complex microenvironment of tumours of the FRT, it
will be necessary to introduce non-malignant cells.
Different co-culture methods to study cell-cell interactions
have been adopted by introducing stromal or immune cells
directly in the ECM droplet together with the organoids
(reviewed in [215]). Other methods include organotypic cul-
tures in which stromal cells (primary or cell lines) are grown
as a monolayer, either on an ECM-coated surface or in a cell
culture insert, and then seeded with epithelial cells. This does
recapitulate essential features of tissues and has been widely
used for the study of the cervix and other stratified tissues
[216, 217]. Bioengineered 3D scaffolds, usually made with
collagen, decellularised tissue or other biomaterials, can also
be used to achieve a more organised tissue (reviewed in
[218]). Co-culture of EO with primary endometrial stromal
cells in a collagen I scaffold has been reported [219]. The
epithelial cells differentiate into ciliated and secretory cells
and both epithelial and stromal cells respond to E2 and P4
by secreting typical proteins associated with decidualisation.
The advantage of this system is that the organoid secretions,
which are normally concentrated within the lumen, are more
accessible. Glandular structures are still absent in this model;
however, it only consists of a single epithelial layer with un-
derlying stroma. A similar approach to how intestinal crypts
have been modelled by using a microengineered scaffold that
guided the growth of primary intestinal cells to recapitulate
crypt-villus organisation may be helpful [220]. Emerging ge-
nomic technologies such as single-cell RNA sequencing and
spatial transcriptomics will provide an important framework
to guide the generation of tissue-like models [120].
Microfluidic systems have also been used to model tissues
in an ‘organ-on-a-chip’ approach. A microfluidics device is a
microchip, with channels moulded into a material to confine
fluid movement. The material that is commonly used for
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culturing cells is poly-di-methyl siloxane which can be
moulded and is biocompatible and permeable to gas. The
main advantage of microfluidic systems is the ability to accu-
rately control the experimental environment allowing for con-
tinuous flow of media and generation of chemical gradients at
a small scale. Furthermore, sensors can be inserted within the
system so specific measurements can be monitored in real-
time. A microfluidic platform that models the entire FRT is
described that uses primary cells to study the endocrine loops
between the various tissues [221]. In order to test the function-
ality of this system, maturation and responses of murine folli-
cles were shown. Similarly, lung and kidney organoids in such
a system allows the study of interactions between multiple cell
types [222, 223]. Challenges remain, however, including the
optimisation of media for different cells, long-term culture and
reproducibility. The application of these models to the FRT
will be essential to address many outstanding questions (Fig.
5).
Organoids to study early pregnancy
The development of FRT organoids together with the recent
advancements in human embryo culture and stem cell-derived
synthetic embryo models provide a unique opportunity to study
the black box of early human development [224–226]. The outer
trophectoderm layer of the blastocyst rapidly establishes contact
with the endometrium, transformed into decidua during pregnan-
cy. Besides providing the site of implantation, secretions from
the luminal epithelium are essential for implantation by providing
growth factors and exosomes [227, 228]. These maternal-fetal
interactions in humans have not been possible to study ex vivo to
date. The derivation of FT and EO now presents an opportunity
to dissect these signals and to study implantation ‘in a dish’ by
co-culture with natural or synthetic embryos. As technologies
develop and push the boundaries of what is possible to achieve
in the laboratory, it is of central importance to also consider the
ethical issues [229, 230].
Upon implantation, the embryo burrows into the decidua and
the formation of the placenta begins. The next stages of the
development of the placenta are also regulated by maternal sig-
nals through decidual glandular secretions [64]. However, the
exact nature of these secretions and their effect on the major cell
type of the placenta, the trophoblast, are unknown. These
maternal-fetal interactions are bidirectional, as signals from the
developing placenta also stimulate the decidua in a positive feed-
back loop [47]. This was demonstrated when human EO were
stimulated with placental products, human chorionic gonadotro-
pin (HCG) and placental lactogen, they differentiated further
resembling ‘pregnant’ decidual glands [50].
The establishment of long-term, genetically stable
organoids of the early human placenta provides an experimen-
tal model to study these early events in vitro [231, 232].
Human placentation is particularly invasive as the extravillous
trophoblast (EVT) of the placenta detach from the villi and
migrate through the decidua to the inner third of the
myometrium [233]. EVT transform the decidual spiral arteries
to allow maximal gaseous/nutrient exchange at the fetal-
maternal interface and this is essential for pregnancy as the
major disorders (pre-eclampsia, miscarriage and still-birth)
show defects in this process [234]. There is little understand-
ing of the molecular and cellular signals between the decidua
and placenta that regulate this complex process. Trophoblast
organoids can differentiate into the two main trophoblast sub-
types: under proliferative conditions, they grow as villous
structures with Ki67+, CDH1+, EpCAM+ mononuclear vil-
lous trophoblast on the outside and the multinucleated
syncytiotrophoblast in the inside. Invasive, human leukocyte
antigen-G+ (HLA-G+) EVT appear either when Wnt signals
are omitted or by using differentiation medium for 2D human
trophoblast stem cells [235]. They also recapitulate key pla-
cental functions: the syncytiotrophoblast secretes placental
products identified by mass spectrometry, as well as resulting
in a positive pregnancy stick. EVT are vigorously invasive,
captured by time-lapse microscopy [231]. The effect of the
decidual and placental signals could be investigated system-
atically using endometrial and trophoblast organoids and stim-
ulating them with recombinant proteins of factors identified
from their secretome. The ultimate goal is to co-culture the
two organoid types together to establish a model of the
maternal-fetal interface.
Conclusions
The FRT undergoes dramatic changes throughout a woman’s
life and its proper function is essential for reproductive health
and wellbeing. Research in this field has been hampered by
the lack of physiologically relevant models together with jus-
tifiable ethical concerns. The generation of organoids of the
FRT that can model both healthy and diseased tissues will be
transformative. The ability of organoids to recapitulate key
anatomical, molecular and functional features of tissues as
well as being amenable to many downstream applications
makes them a powerful model system. Organoids are more
expensive and labour intensive than 2D cell lines but the tech-
nique is relatively simple and can be easily adopted by other
labs. As we move forward with these tools, it is imperative
that we also continue to address issues including reproducibil-
ity and thorough comparisons with tissues to benchmark and
improve the organoid models [120, 236]. Furthermore, inter-
disciplinary approaches such as bioengineering to incorporate
multiple cell types will help further develop these models.
FRT organoids will allow us to investigate the fundamental
biology of how these tissues function, how the different cell
types interact, as well as gaining insight into the pathogenesis
of cancer and infectious diseases. They also provide
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translational opportunities in drug discovery and personalised
medicine. These emerging tools open up new possibilities to
address outstanding questions in the research field of the FRT,
thereby providing great promise for improving the health and
wellbeing of women.
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